Novocure Ltd
NVCR12.040USD
-0.500-3.99%
Fechamento 07/25, 16:00（ET）Cotações atrasadas em 15 min
1.35BValor de mercado
PerdaP/L TTM
Mais detalhes de Novocure Ltd Empresa
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Informações da empresa
Código da empresaNVCR
Nome da EmpresaNovocure Ltd
Data de listagemOct 01, 2015
Fundado em2000
CEOMs. Ashley Cordova
Número de funcionários1488
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 01
EndereçoNo. 4 The Forum
CidadeSAINT HELIER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísJersey
Código postalJE2 4UF
Telefone441534756700
Sitehttps://www.novocure.com/
Código da empresaNVCR
Data de listagemOct 01, 2015
Fundado em2000
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
93.15M
60.10%
Germany
18.72M
12.08%
France
17.86M
11.52%
Other EMEA countries
11.94M
7.70%
Japan
8.71M
5.62%
Greater China
4.62M
2.98%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 23 de jul
Atualizado em: qua, 23 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
Tipos de investidores
Investidores
Proporção
Investment Advisor
48.81%
Investment Advisor/Hedge Fund
14.72%
Hedge Fund
12.72%
Individual Investor
10.05%
Research Firm
1.57%
Sovereign Wealth Fund
0.87%
Pension Fund
0.42%
Bank and Trust
0.32%
Venture Capital
0.12%
Other
10.39%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
675
112.27M
100.70%
-3.75M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
2023Q1
864
93.47M
88.04%
+2.38M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
16.49M
14.79%
+257.14K
+1.58%
Mar 31, 2025
The Vanguard Group, Inc.
11.23M
10.07%
-544.61K
-4.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.78M
7.88%
-135.87K
-1.52%
Mar 31, 2025
Wyss (Hansjorg)
8.14M
7.3%
--
--
Apr 04, 2025
Soleus Capital Management, L.P.
5.52M
4.95%
+2.78M
+101.53%
Mar 31, 2025
Capital World Investors
5.22M
4.68%
+400.00K
+8.31%
Mar 31, 2025
State Street Global Advisors (US)
2.59M
2.32%
-52.73K
-2.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.46M
2.21%
+63.41K
+2.64%
Mar 31, 2025
BlackRock Financial Management, Inc.
2.06M
1.85%
+71.86K
+3.61%
Mar 31, 2025
Marshall Wace LLP
1.81M
1.62%
+1.54M
+567.13%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Global X HealthTech ETF
1.92%
SPDR S&P Health Care Equipment ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.63%
Amplify BlueStar Israel Technology ETF
0.93%
iShares Health Innovation Active ETF
0.53%
VanEck Israel ETF
0.42%
First Trust Small Cap Growth AlphaDEX Fund
0.34%
Global X Aging Population ETF
0.34%
Nuveen ESG Small-Cap ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
Ver Mais
Global X HealthTech ETF
Proporção1.92%
SPDR S&P Health Care Equipment ETF
Proporção1.85%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.63%
Amplify BlueStar Israel Technology ETF
Proporção0.93%
iShares Health Innovation Active ETF
Proporção0.53%
VanEck Israel ETF
Proporção0.42%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.34%
Global X Aging Population ETF
Proporção0.34%
Nuveen ESG Small-Cap ETF
Proporção0.25%
ProShares Ultra Nasdaq Biotechnology
Proporção0.23%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
